Drugs / anti-FcRL5 CAR-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06196255 | Dec 2023 → Jan 2027 expected | plasma cell myeloma | Xuzhou Medical University | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anti-FcRL5 CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06196255 ↗ |
| Modality | Cell therapy | “Anti-FcRL5 chimeric antigen receptor (CAR) modified T cells.” NCT06196255 ↗ |